The Clinical Research Institutions Exhibition and Guangzhou Clinical Research Industry Transaction Fair (referred to as "CRE") is a specialized exhibition under the Guangzhou Healthcare and Health Industry Expo. It is hosted by the Guangzhou Municipal People's Government, organized by the Guangzhou Municipal Health Commission, the Guangzhou Cooperation Office, and the Guangzhou International Fair Organizing Committee Office. It is undertaken by Guangdong Global Sourcing Exhibition Co., Ltd. and Guangdong Yinling Health Industry Co., Ltd. The CRE will be held grandly from August 21st to 23rd, 2026, at the China Import and Export Fair Complex in Guangzhou.

The CRE has received strong support from leaders at various levels, including the National Health Commission, the Guangzhou Municipal People's Government, the Guangdong Provincial Health Commission, the Guangzhou Municipal Health Commission, the Guangzhou Municipal Medical Security Bureau, the Guangzhou Municipal Industry and Information Technology Bureau, and the Guangzhou Municipal Science and Technology Bureau. Since its inception, it has attracted over 140,000 visits, drawing GCP institutions, CROs, SMOs, sponsors, clinical trial service providers, media, and industry professionals for exchange. It has facilitated the signing of over 1,000 project cooperation letters of intent. The CRE explicitly aims to facilitate the negotiation, transaction, and cooperation of clinical research projects, assisting in the connection between healthcare institutions and enterprises for clinical research projects.

Event Background
01 China's Clinical Research Industry Enters a New Stage of High-Quality Development: Driven by continuous policy optimization and strong market forces, China's clinical research industry has transitioned from a period of rapid growth to a new cycle emphasizing quality and efficiency improvement. According to the latest data from the National Medical Products Administration, China's pharmaceutical R&D investment consistently ranks among the top globally, with both the quantity and quality of Investigational New Drug (IND) applications increasing. Activity is particularly vigorous in cutting-edge fields such as cell and gene therapy and ADC (antibody-drug conjugate). With the deepening exploration of new models like real-world research (RWR) and decentralized clinical trials (DCT), China not only consolidates its position as a significant force in global R&D but also shows immense potential in leading the transformation of clinical research paradigms.
02 Guangzhou Accelerates Building a Globally Influential Clinical Research Innovation Hub: Guangzhou has become a "new hotspot" for global biomedicine, possessing abundant medical resources, robust scientific research capabilities, and a solid industrial foundation. As of 2025, Guangzhou is home to 48 tertiary grade-A hospitals, 8 national medical centers and regional medical centers, and over 6,500 biomedicine enterprises. In recent years, Guangzhou has actively deployed its clinical research industry, constructing a number of high-level clinical research platforms and attracting many outstanding clinical research institutions and enterprises to establish a presence. It is committed to building a world-class clinical research industry ecosystem.
03 Collaborative Creation of a New, Efficiently Integrated Clinical Research Ecosystem: To date, more than 1,600 medical institutions nationwide have completed filing for drug and medical device clinical trial institution qualifications, with over 30,000 filed investigators. Established institutions need to build their brands, while many others urgently need to achieve a breakthrough from zero by expanding project collaboration sources. For medical institutions developing clinical research industries, cooperation with high-quality supporting suppliers in IT and achievement transformation is also needed. Furthermore, as competition among biomedicine enterprises intensifies, there is a pressing need to improve R&D efficiency and reduce clinical operational costs. By centrally organizing clinical research institutions and enterprises to exhibit, facilitating full exchange and transactions between the supply and demand sides of clinical research resources, it will undoubtedly promote the integrated development of the clinical research industry.

Organizational Structure
Host: Guangzhou Municipal People's Government
Responsible Units: Guangzhou Municipal Health Commission, Guangzhou Cooperation Office, Guangzhou International Fair Organizing Committee Office
Undertaking Units: Guangdong Global Sourcing Exhibition Co., Ltd., Guangdong Yinling Health Industry Co., Ltd.

Highlights: Multi-Dimensional Activities Outline the Industry Panorama
01 Official Backing: Hosted by the Guangzhou Municipal People's Government and organized by the Guangzhou Municipal Health Commission, Guangzhou Cooperation Office, and Guangzhou International Fair Organizing Committee Office. Official invitations are sent to medical institutions, enterprise representatives, and health bureaus from various cities and districts in Guangzhou to participate as groups.
02 Four-Level Tour: Organizes four major touring groups composed of leaders from national/provincial/municipal relevant departments, hospital presidents, medical experts, and executives from state-owned enterprises, central enterprises, and multinational pharmaceutical/medical device companies to visit exhibition areas. This provides one-stop access to the four major ecosystems: government, medical, research, and enterprise.
03 Exhibition Positioning: The nation's "first" clinical research industry brand exhibition. The CRE explicitly aims for clinical research project negotiation/transaction, cooperation exchange, and partner networking, promoting extensive understanding and collaborative exchange among clinical research institutions, CROs, and sponsors.
04 Authoritative Releases: Invites industry regulatory authorities to release data on the clinical research industry of medical institutions. Invites comprehensive hospitals, specialized hospitals, and primary care hospitals with successful clinical research industrialization development to share experiences.
05 Meeting and Exchange: Arranges for municipal leaders and hospital presidents to meet respectively with representatives of some exhibiting units during the exhibition, providing exhibitors an opportunity for direct dialogue with decision-makers.
06 Audience Organization: Precisely invites senior professionals responsible for clinical research operations and management from pharmaceutical and medical device enterprises. Also organizes group participation through industry associations, societies, and parks.
07 Free Registration: To attract more industry professionals and enhance on-site exchange and transaction atmosphere, the CRE sets no participation threshold. It provides free registration services for forums and exhibition areas, allowing more professionals to participate in this important industry exchange event.
08 Matrix Promotion: Implements all-media, multi-level matrix promotion. Integrates official media, mainstream media, new media, and industry media to build an all-media matrix. Promotes the CRE and concurrent forum activities before, during, and after the event to enhance visibility and expand influence.

Concurrent Core Conferences, Co-creating a New Clinical Research Industry Ecosystem
This edition of the CRE will concurrently host a series of high-end, professional thematic conferences, providing a platform for comprehensive idea碰撞 and experience sharing for participants.

• Guangzhou Healthcare Expo Opening Ceremony & Theme Conference

• "Greater Bay Area Drug and Medical Device Access" Policy Practice Sharing Session

• Cell and Gene Therapy Technology Frontier Seminar

• Clinical Trial High-Quality Development Exchange Event

• Medical Aesthetics and Skin Health Industry Conference

• AI Drug Discovery and Clinical Trial Innovation Symposium

• Guangzhou District Biomedicine Industry Policy Briefings

• Wound Repair and Tissue Regeneration Innovation Conference

• Specific event schedule is subject to on-site arrangements.

Exhibition Scope
(1) Medical Institutions: Medical institutions with GCP qualifications or other medical institutions intending to develop clinical research industries.
(2) Related Biomedicine Technology R&D Enterprises: Pharmaceutical companies, medical device companies, stem cell/somatic cell drug R&D companies, etc.
(3) Suppliers Providing Clinical Research Products and Services: Clinical trial institution filing guidance and consulting agencies, Contract Research Organizations (CROs), Academic Research Organizations (AROs), clinical research informatization system and solution suppliers, data management, biostatistics, and pharmacovigilance companies, biological sample testing companies, Site Management Organizations (SMOs), clinical trial insurance, cold chain/logistics/biological sample storage suppliers, biomedicine parks, literature search/medical writing/medical translation, intellectual property affairs/legal services/registration application and other achievement transformation service agencies, R&D units undertaking medical institution achievement transformation, investment and financing institutions.
(4) Achievement Transformation Related Institutions and Service Providers: Medical institution achievement transformation displays (including innovative achievements in medical technology, diagnostic methods, treatment methods, drug R&D, medical device improvement, etc.), cooperation projects and outcomes between medical institutions and other research institutions, enterprises, government departments, etc., achievement transformation service agencies, R&D units undertaking medical institution achievement transformation, investment and financing institutions.

Visitor Profile
(1) Clinical Research Industry: Hospital leadership in charge of clinical research at medical institutions, heads of relevant departments managing clinical research, department/disciplinary academic leaders/investigators, clinical research industry chain suppliers, clinical research-related professionals (sponsor, CRO, and SMO clinical operations directors, PMs, SSU leads, institutional partnership leads, post-marketing project leads, medical, BD, QA, CRAs, CRCs, etc.).
(2) Government Units: Leaders or department representatives from relevant government departments such as Health Commissions, Drug Administration, Science and Technology Bureau, Industry and Information Technology Bureau, Civil Affairs Bureau, Development and Reform Commission, Medical Security Bureau, etc.
(3) Others: Hospitals and medical institutions, medical-rehabilitation-elderly care institutions, social organizations, medical channel distributors, investment and trade institutions, parks, etc.